Shamburg News · 8-K filed Nov 12, 2026, 4:20 PM EST
Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Update
SCTX · Scribe Therapeutics, Inc.
- Earnings
- Materiality: high
Scribe Therapeutics Inc. reported financial results for the quarter ended September 30, 2026, with collaboration revenue of $1.6 million and a net loss of $9.9 million, or $0.68 per basic and diluted share. Cash, cash equivalents, and marketable securities were $174.2 million as of September 30, 2026, which the company expects to fund operations into the first half of 2029. The results were furnished in Exhibit 99.1 under Item 2.02.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-458486.
Written from the filing by Shamburg Markets. Figures are as reported by the company.